Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Free Cash Flow: 2020-2024

Historic Free Cash Flow for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to -$44.2 million.

  • Janux Therapeutics' Free Cash Flow fell 473.98% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71.4 million, marking a year-over-year decrease of 88.77%. This contributed to the annual value of -$44.2 million for FY2024, which is 15.74% up from last year.
  • Per Janux Therapeutics' latest filing, its Free Cash Flow stood at -$44.2 million for FY2024, which was up 15.74% from -$52.4 million recorded in FY2023.
  • Janux Therapeutics' 5-year Free Cash Flow high stood at -$4.5 million for FY2020, and its period low was -$52.4 million during FY2023.
  • Its 3-year average for Free Cash Flow is -$48.7 million, with a median of -$49.4 million in 2022.
  • As far as peak fluctuations go, Janux Therapeutics' Free Cash Flow crashed by 308.72% in 2021, and later grew by 15.74% in 2024.
  • Janux Therapeutics' Free Cash Flow (Yearly) stood at -$4.5 million in 2020, then tumbled by 308.72% to -$18.5 million in 2021, then tumbled by 167.46% to -$49.4 million in 2022, then decreased by 6.19% to -$52.4 million in 2023, then rose by 15.74% to -$44.2 million in 2024.